Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2011, Article ID 301695, 6 pages
http://dx.doi.org/10.1155/2011/301695
Clinical Study

Phosphodiesterase Type 4D Gene Polymorphism: Association with the Response to Short-Acting Bronchodilators in Paediatric Asthma Patients

1Research Center, CHU Sainte-Justine, Montreal, QC, Canada H3T 1C5
2Department of Paediatrics, University of Montreal, Montreal, Qc, Canada H3T 1C5
3Department of Human Genetics, McGill University and Génome Québec Innovation Centre, Montreal, Qc, Canada H3A 1A4
4Department of Pharmacology, University of Montreal, Montreal, Qc, Canada H3T 1J4

Received 27 January 2011; Revised 16 June 2011; Accepted 1 July 2011

Academic Editor: E. Moilanen

Copyright © 2011 Malgorzata Labuda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. T. Weiss, “Gene by environment interaction and asthma,” Clinical and Experimental Allergy, vol. 29, supplement 2, pp. 96–98, 1999. View at Google Scholar · View at Scopus
  2. M. D. Houslay, “Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown,” Trends in Biochemical Sciences, vol. 35, no. 2, pp. 91–100, 2011. View at Publisher · View at Google Scholar
  3. M. D. Houslay and D. R. Adams, “PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization,” Biochemical Journal, vol. 370, part 1, pp. 1–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. S. J. MacKenzie, G. S. Baillie, I. McPhee et al., “Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1),” British Journal of Pharmacology, vol. 136, no. 3, pp. 421–433, 2002. View at Google Scholar · View at Scopus
  5. M. Conti and S. L. Jin, “The molecular biology of cyclic nucleotide phosphodiesterases,” Progress in Nucleic Acid Research and Molecular Biology, vol. 63, pp. 1–38, 1999. View at Google Scholar · View at Scopus
  6. M. D. Houslay, “PDE4 cAMP-specific phosphodiesterases,” Progress in Nucleic Acid Research and Molecular Biology, vol. 69, pp. 249–315, 2001. View at Google Scholar · View at Scopus
  7. M. D. Houslay, “The long and short of vascular smooth muscle phosphodiesterase-4 as a putative therapeutic target,” Molecular Pharmacology, vol. 68, no. 3, pp. 563–567, 2005. View at Publisher · View at Google Scholar
  8. I. R. Le Jeune, M. Shepherd, G. van Heeke, M. D. Houslay, and I. P. Hall, “Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells: identification and characterization of a novel PDE4D5 promoter,” Journal of Biological Chemistry, vol. 277, no. 39, pp. 35980–35989, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Méhats, S. L. Jin, J. Wahlstrom, E. Law, D. T. Umetsu, and M. Conti, “PDE4D plays a critical role in the control of airway smooth muscle contraction,” FASEB Journal, vol. 17, no. 13, pp. 1831–1841, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. T. J. Torphy, B. J. Undem, L. B. Cieslinski, M. A. Luttmann, M. L. Reeves, and D. W. Hay, “Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle,” Journal of Pharmacology and Experimental Therapeutics, vol. 265, no. 3, pp. 1213–1223, 1993. View at Google Scholar · View at Scopus
  11. C. K. Billington, I. R. Le Jeune, K. W. Young, and I. P. Hall, “A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 38, no. 1, pp. 1–7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. G. S. Baillie, A. Sood, I. McPhee et al., “β-arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates β-adrenoceptor switching from Gs to Gi,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 3, pp. 940–945, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. M. J. Lynch, G. S. Baillie, A. Mohamed et al., “RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with βarrestin to control the protein kinase A/AKAP79-mediated switching of the β2-adrenergic receptor to activation of ERK in HEK293B2 cells,” Journal of Biological Chemistry, vol. 280, no. 39, pp. 33178–33189, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Hansen, S. L. Jin, D. T. Umetsu, and M. Conti, “Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 12, pp. 6751–6756, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Gretarsdottir, G. Thorleifsson, S. T. Reynisdottir et al., “The gene encoding phosphodiesterase 4D confers risk of ischemic stroke,” Nature Genetics, vol. 35, no. 2, pp. 131–138, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. R. H. Reneland, S. Mah, S. Kammerer et al., “Association between a variation in the phosphodiesterase 4D gene and bone mineral density,” BMC Medical Genetics, vol. 6, article 9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Homma, T. Sakamoto, A. E. Hegab et al., “Association of phosphodiesterase 4D gene polymorphisms with chronic obstructive pulmonary disease: relationship to interleukin 13 gene polymorphism,” International Journal of Molecular Medicine, vol. 18, no. 5, pp. 933–939, 2006. View at Google Scholar · View at Scopus
  18. B. E. Himes, G. M. Hunninghake, J. W. Baurley et al., “Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene,” American Journal of Human Genetics, vol. 84, no. 5, pp. 581–593, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Munshi and S. Kaul, “Stroke genetics—focus on PDE4D gene,” International Journal of Stroke, vol. 3, no. 3, pp. 188–192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. M. D. Houslay, P. Schafer, and K. Y. Zhang, “Keynote review: phosphodiesterase-4 as a therapeutic target,” Drug Discovery Today, vol. 10, no. 22, pp. 1503–1519, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. R. E. Weishaar, M. H. Cain, and J. A. Bristol, “A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity,” Journal of Medicinal Chemistry, vol. 28, no. 5, pp. 537–545, 1985. View at Google Scholar · View at Scopus
  22. D. Spina, “PDE4 inhibitors: current status,” British Journal of Pharmacology, vol. 155, no. 3, pp. 308–315, 2008. View at Publisher · View at Google Scholar
  23. B. J. Lipworth, “Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease,” Lancet, vol. 365, no. 9454, pp. 167–175, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. R. W. Chapman, A. House, J. Richard et al., “Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration,” European Journal of Pharmacology, vol. 643, no. 2-3, pp. 274–281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Chong, P. Poole, B. Leung, and P. N. Black, “Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease,” Cochrane Database of Systematic Reviews, vol. 5, Article ID CD002309, 2011. View at Google Scholar
  26. A. Hatzelmann, E. J. Morcillo, G. Lungarella et al., “The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease,” Pulmonary Pharmacology and Therapeutics, vol. 23, no. 4, pp. 235–256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. A. T. Nials, C. J. Tralau-Stewart, M. H. Gascoigne, D. I. Ball, L. E. Ranshaw, and R. G. Knowles, “In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor,” Journal of Pharmacology and Experimental Therapeutics, vol. 337, no. 1, pp. 137–144, 2011. View at Publisher · View at Google Scholar
  28. M. R. Miller, J. Hankinson, V. Brusasco et al., “Standardisation of spirometry,” European Respiratory Journal, vol. 26, no. 2, pp. 319–338, 2005. View at Publisher · View at Google Scholar
  29. National Asthma Education and Prevention Program, “Expert Panel report 3: guidelines for the diagnosis and management of asthma,” U.S. Department of Health and Humane Services, National Institutes of Health, National Heart, Lung, and Blood Institute, 2007.
  30. L. B. Bacharier, A. Boner, K. H. Carlsen et al., “Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report,” Allergy, vol. 63, no. 1, pp. 5–34, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Polgar and V. Promadath, Pulmonary Function Testing in Children: Techniques and Standards, WB Saunders, Philadelphia, Pa, USA, 1974.
  32. S. Bourgeois and D. Labuda, “Dynamic allele-specific oligonucleotide hybridization on solid support,” Analytical Biochemistry, vol. 324, no. 2, pp. 309–311, 2004. View at Publisher · View at Google Scholar
  33. M. D. Lougheed, C. Lemiere, S. D. Dell et al., “Canadian Thoracic Society Asthma Committee commentary on long-acting beta-2 agonist use for asthma in Canada,” Canadian Respiratory Journal, vol. 17, no. 1, pp. 15–24, 2010. View at Google Scholar
  34. R. Pellegrino, G. Viegi, V. Brusasco et al., “Interpretative strategies for lung function tests,” European Respiratory Journal, vol. 26, no. 5, pp. 948–968, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. A. A. Litonjua, J. Lasky-Su, K. Schneiter et al., “ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 7, pp. 688–694, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. P. H. Lee and H. Shatkay, “F-SNP: computationally predicted functional SNPs for disease association studies,” Nucleic Acids Research, vol. 36, no. 1, pp. D820–D824, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Ge, D. K. Pokholok, T. Kwan et al., “Global patterns of cis variation in human cells revealed by high-density allelic expression analysis,” Nature Genetics, vol. 41, no. 11, pp. 1216–1222, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Grundberg, V. Adoue, T. Kwan et al., “Global analysis of the impact of environmental perturbation on cis-regulation of gene expression,” PLoS Genetics, vol. 7, no. 1, Article ID e1001279, 2011. View at Publisher · View at Google Scholar